Do you want to read an article? Please log in or register.
Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III randomized controlled trials
Gastrointestinal Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 2
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lancet
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, KEYNOTE-671 Investigators
doi: 10.1016/S0140-6736(24)01756-2
Lung, Respiratory and Thoracic Cancer
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies
Lung Cancer
Akamatsu H, Nishikawa T, Takeda Y, Misumi T, Aoki T, Shoda H, Yamashita M, Sakakura N, Daga H, Sugawara S, Okishio K, Kenmotsu H, Yamamoto N, Tada H, Tsuboi M, Mitsudomi T
doi: 10.1016/j.lungcan.2025.108437
Lung, Respiratory and Thoracic Cancer
Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis
Cancers (Basel)
Girard N, Besada M, Rogula B, Lucherini S, Vo L, Chaudhary MA, Goring S, Lozano-Ortega G, Tran M, Varol N, Waser N, Lee JM, Spicer J
doi: 10.3390/cancers16132492
Breast Cancer
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
Ann Oncol
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D
doi: 10.1016/j.annonc.2024.10.015
Further Publications
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials
Eur J Cancer
Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, Dapper H, Germer CT, Grützmann R, Tim Friede J, Joshua Smith J, Saltz LB, Wu AJ, Weiser MR, Omer D, Ghadimi M, Hofheinz RD, Garcia-Aguilar J, Rödel C, German Rectal Cancer Study Group and the OPRA Consortium
doi: 10.1016/j.ejca.2024.114291
Gynecologic Cancer
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
Eur J Cancer
Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Maćkowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS
doi: 10.1016/j.ejca.2024.115146
Gastrointestinal Cancer
Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer
Int J Cancer
Noronha V, Patil VM, Menon N, Goud S, Singh A, Shah M, More S, Shah S, Yadav A, Sonawane S, Nawale K, Chowdhury OR, Kaushal RK, Ghosh-Laskar S, Agarwal JP, Yadav S, Pai T, Janu A, Mahajan A, Purandare N, Banavali S, Badwe R, Prabhash K
doi: 10.1002/ijc.35111
Skin Cancer
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Lancet Oncol
Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM
doi: 10.1016/S1470-2045(24)00338-3
Gastrointestinal Cancer
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY
J Clin Oncol
Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Cheong JH, Jeong O, Heo MH, Kim HK, Park C, Yoo CH, Kang SY, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Hwang JE, Ryu SW, Kook MC, Ryoo BY, Kim H, Yoo MW, Lee NS, Lee SH, Noh SH
doi: 10.1200/JCO.23.02167